Published in J Am Coll Cardiol on February 19, 2013
Rate control in atrial fibrillation, insight into the RACE II study. Neth Heart J (2013) 0.79
Avoiding permanent atrial fibrillation: treatment approaches to prevent disease progression. Vasc Health Risk Manag (2013) 0.78
Managing atrial fibrillation in the very elderly patient: challenges and solutions. Vasc Health Risk Manag (2015) 0.77
[Which heart rate in atrial fibrillation?]. MMW Fortschr Med (2013) 0.75
Rate control for permanent atrial fibrillation: a Race (II) worth running? J Am Coll Cardiol (2013) 0.75
Current Evidence and Recommendations for Rate Control in Atrial Fibrillation. Arrhythm Electrophysiol Rev (2013) 0.75
Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med (2009) 39.97
Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med (2013) 20.65
Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J (2010) 16.39
Subclinical atrial fibrillation and the risk of stroke. N Engl J Med (2012) 11.11
A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest (2010) 10.29
Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med (2011) 8.93
Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med (2002) 8.72
Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med (2009) 8.51
A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med (2002) 8.37
Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med (2010) 8.17
Early invasive versus selectively invasive management for acute coronary syndromes. N Engl J Med (2005) 7.80
Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation (2011) 6.48
Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int (2004) 6.32
Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace (2010) 6.31
Prognostic association of depression following myocardial infarction with mortality and cardiovascular events: a meta-analysis. Psychosom Med (2004) 6.00
Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med (2007) 5.78
An entirely subcutaneous implantable cardioverter-defibrillator. N Engl J Med (2010) 5.32
European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace (2013) 5.16
Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J (2005) 4.46
Effects of antidepressant treatment following myocardial infarction. Br J Psychiatry (2007) 4.44
Effects of early high-volume continuous venovenous hemofiltration on survival and recovery of renal function in intensive care patients with acute renal failure: a prospective, randomized trial. Crit Care Med (2002) 4.33
Global incidences of out-of-hospital cardiac arrest and survival rates: Systematic review of 67 prospective studies. Resuscitation (2010) 3.98
Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J (2005) 3.89
Culprit vessel only versus multivessel and staged percutaneous coronary intervention for multivessel disease in patients presenting with ST-segment elevation myocardial infarction: a pairwise and network meta-analysis. J Am Coll Cardiol (2011) 3.66
B-type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction. J Am Coll Cardiol (2013) 3.54
Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clin Res Cardiol (2010) 3.50
Increased central venous pressure is associated with impaired renal function and mortality in a broad spectrum of patients with cardiovascular disease. J Am Coll Cardiol (2009) 3.31
Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. Circulation (2013) 3.25
A systematic review and meta-analysis of intra-aortic balloon pump therapy in ST-elevation myocardial infarction: should we change the guidelines? Eur Heart J (2009) 3.06
Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation (2004) 3.05
Genome-wide association analyses identify 18 new loci associated with serum urate concentrations. Nat Genet (2012) 3.04
Presence of older thrombus is an independent predictor of long-term mortality in patients with ST-elevation myocardial infarction treated with thrombus aspiration during primary percutaneous coronary intervention. Circulation (2008) 2.96
Diagnostic accuracy of combined intracoronary pressure and flow velocity information during baseline conditions: adenosine-free assessment of functional coronary lesion severity. Circ Cardiovasc Interv (2012) 2.93
Evaluation of the accuracy of gadolinium-enhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis. J Am Coll Cardiol (2005) 2.93
Randomized trial comparing same-day discharge with overnight hospital stay after percutaneous coronary intervention: results of the Elective PCI in Outpatient Study (EPOS). Circulation (2007) 2.90
Chronic vagus nerve stimulation: a new and promising therapeutic approach for chronic heart failure. Eur Heart J (2010) 2.86
Meta-analysis of clinical characteristics of 299 carriers of LMNA gene mutations: do lamin A/C mutations portend a high risk of sudden death? J Mol Med (Berl) (2004) 2.81
Worsening renal function and prognosis in heart failure: systematic review and meta-analysis. J Card Fail (2007) 2.77
Two-year clinical outcomes of Absorb bioresorbable vascular scaffold implantation in complex coronary artery disease patients stratified by SYNTAX score and ABSORB II study enrolment criteria. EuroIntervention (2016) 2.67
The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study. Circulation (2013) 2.64
Anemia and mortality in heart failure patients a systematic review and meta-analysis. J Am Coll Cardiol (2008) 2.59
Progression from paroxysmal to persistent atrial fibrillation clinical correlates and prognosis. J Am Coll Cardiol (2010) 2.59
EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary. Eur Heart J (2013) 2.52
A single dose of erythropoietin in ST-elevation myocardial infarction. Eur Heart J (2010) 2.52
Management of chronic heart failure guided by individual N-terminal pro-B-type natriuretic peptide targets: results of the PRIMA (Can PRo-brain-natriuretic peptide guided therapy of chronic heart failure IMprove heart fAilure morbidity and mortality?) study. J Am Coll Cardiol (2010) 2.50
Cardiac involvement in patients with pulmonary sarcoidosis assessed at two university medical centers in the Netherlands. Chest (2005) 2.50
Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial. Ann Intern Med (2011) 2.45
Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. Eur Heart J (2013) 2.45
Aortic stiffness and diameter predict progressive aortic dilatation in patients with Marfan syndrome. Eur Heart J (2004) 2.44
Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention. N Engl J Med (2006) 2.42
Symptom dimensions of depression following myocardial infarction and their relationship with somatic health status and cardiovascular prognosis. Am J Psychiatry (2006) 2.41
Drawbacks and prognostic value of formulas estimating renal function in patients with chronic heart failure and systolic dysfunction. Circulation (2006) 2.35
Microalbuminuria and risk of venous thromboembolism. JAMA (2009) 2.35
Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace (2015) 2.35
Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND. Eur Heart J (2013) 2.32
Thrombospondin-2 is essential for myocardial matrix integrity: increased expression identifies failure-prone cardiac hypertrophy. Circ Res (2004) 2.31
Comparison between the prognostic value of left ventricular function and myocardial perfusion reserve in patients with ischemic heart disease. J Nucl Med (2009) 2.31
Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation (2004) 2.30
Design and methodology of the COACH study: a multicenter randomised Coordinating study evaluating Outcomes of Advising and Counselling in Heart failure. Eur J Heart Fail (2004) 2.30
Relationship between left ventricular dysfunction and depression following myocardial infarction: data from the MIND-IT. Eur Heart J (2005) 2.28
Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial. Eur Heart J (2013) 2.27
Effect of moderate or intensive disease management program on outcome in patients with heart failure: Coordinating Study Evaluating Outcomes of Advising and Counseling in Heart Failure (COACH). Arch Intern Med (2008) 2.23
Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med (2010) 2.21
Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J (2011) 2.21
Effect of lenient versus strict rate control on cardiac remodeling in patients with atrial fibrillation data of the RACE II (RAte Control Efficacy in permanent atrial fibrillation II) study. J Am Coll Cardiol (2011) 2.19
Prognostic value of coronary blood flow velocity and myocardial perfusion in intermediate coronary narrowings and multivessel disease. J Am Coll Cardiol (2002) 2.18
Who is at risk of post-MI depressive symptoms? J Psychosom Res (2005) 2.18
Long-term outcome of a routine versus selective invasive strategy in patients with non-ST-segment elevation acute coronary syndrome a meta-analysis of individual patient data. J Am Coll Cardiol (2010) 2.17
Atrial fibrillation and heart failure in cardiology practice: reciprocal impact and combined management from the perspective of atrial fibrillation: results of the Euro Heart Survey on atrial fibrillation. J Am Coll Cardiol (2009) 2.16
Effect of rate or rhythm control on quality of life in persistent atrial fibrillation. Results from the Rate Control Versus Electrical Cardioversion (RACE) Study. J Am Coll Cardiol (2004) 2.10
Strategic programming of detection and therapy parameters in implantable cardioverter-defibrillators reduces shocks in primary prevention patients: results from the PREPARE (Primary Prevention Parameters Evaluation) study. J Am Coll Cardiol (2008) 2.10
Continuous vs episodic prophylactic treatment with amiodarone for the prevention of atrial fibrillation: a randomized trial. JAMA (2008) 2.09
Preprocedural C-reactive protein is not associated with angiographic restenosis or target lesion revascularization after coronary artery stent placement. Clin Chem (2004) 2.08